Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

50.08 -1.12 (-2.19%)
Streaming Delayed Price Updated: 1:05 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 280,889
Open 50.88
Bid (Size) 50.04 (100)
Ask (Size) 50.13 (300)
Prev. Close 51.20
Today's Range 50.02 - 50.88
52wk Range 30.83 - 59.68
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Growth Stocks We Approach with Caution
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
News headline image
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year ↗
Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+1.2%
+1.2%
1 Month
-0.1%
-0.1%
3 Month
+0.5%
+0.5%
6 Month
+12.7%
+12.7%
1 Year
+58.8%
+58.8%

More News

Read More
News headline image
5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call
Via StockStory
Topics Earnings Supply Chain
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Q1 Estimates as Growth Products Drive 39% Revenue Surge ↗
Via Chartmill
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Posts Strong Q4 Beat as CNS Portfolio Accelerates Growth ↗
Via Chartmill
News headline image
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today
Via StockStory
Topics Earnings Economy
News headline image
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SUPN Q1 Deep Dive: Growth Products Drive Revenue Upside, Guidance Highlights Execution Challenges
Via StockStory
Topics Economy Supply Chain
News headline image
1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges
Via StockStory
News headline image
Supernus (SUPN) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates
Via StockStory
Topics Earnings
News headline image
Supernus Announces First Quarter 2026 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
Via StockStory
Topics Artificial Intelligence
News headline image
Branded Pharmaceuticals Stocks Q4 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know
Via StockStory
Topics Economy
News headline image
3 Unprofitable Stocks We Think Twice About
Via StockStory
News headline image
1 Cash-Producing Stock to Consider Right Now and 2 Facing Headwinds
Via StockStory
News headline image
Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Reasons SUPN is Risky and 1 Stock to Buy Instead
Via StockStory
Topics Stocks Supply Chain
News headline image
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales
Via StockStory
News headline image
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals to Participate in March Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
Topics Artificial Intelligence
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Via Investor Brand Network
Topics Intellectual Property

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 50.08
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 05/15/26 01:05 PM ET
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.66B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.